# Neuroimaging Core

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $547,090

## Abstract

Project Summary – Neuroimaging Core (NIC)
The Neuroimaging Core (NIC) of the IADC brings advanced imaging tools in support of the goal of effectively
preventing and treating AD by 2025. The NIC has been productive in developing and implementing leading-
edge imaging protocols and imaging genetics analysis techniques, collaborating with NIA-funded initiatives
(e.g., ADNI, DIAN, ADGC, etc.), and in providing training in neuroimaging and imaging genetics to scientists of
all levels (undergraduate to faculty) and disciplines (neuroscience, genetics, computer science, physicians,
etc.). In the next funding period the NIC will continue to pursue the following specific aims: (1) Support funded
research in the IADC, IU Center for Aging Research, and related programs that currently employ or could
benefit from advanced neuroimaging; (2) Provide standardized, state-of-the-art neuroimaging acquisition and
analysis protocols; (3) Expand transdisciplinary regional neuroscience research using advanced neuroimaging
tools to study disease mechanisms and treatments for neurodegeneration; (4) Support and collaborate with
major national and international AD-related research consortia using neuroimaging and genetics methods; (5)
Provide transdisciplinary educational opportunities in neuroimaging and genetics of AD and other degenerative
disorders for basic and clinical scientists at all levels from undergraduates to post-doctoral fellows and faculty,
as well as dissemination of neuroimaging results to the community. The NIC, working closely with the Clinical
Core, will perform state-of-the-art advanced multimodal MRI ( Siemens Prisma 3T: high resolution structural
and 3D pCASL perfusion, multiband resting-state and task-based fMRI, and DTI optimized for structural and
functional connectome analysis) on all eligible IADC participants, as well as amyloid and/or tau PET on 225
IADC participants. Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline
(SCD) or with mild cognitive impairment (MCI)), late-onset AD, and individuals from families with mutations
causal for dementias will be prioritized. Imaging-pathologic correlation when available will improve the
understanding of early structural, functional, and molecular changes observed in vivo and may help identify
novel therapeutic targets. Cross-modality image analyses and results of imaging genetics studies with ADNI,
DIAN, and other partners will contribute to advances in early detection, mechanistic understanding, and
optimized use of imaging as a dynamic biomarker for the study of therapeutic effects. Acquiring standardized
state-of-the-art MRI and PET data for use by many investigators will increase research productivity and
facilitate the optimized quantitative analyses. Close integration with other cores will further allow the IADC to
expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic
samples, genetic and other –omics mark...

## Key facts

- **NIH application ID:** 9977803
- **Project number:** 5P30AG010133-30
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** ANDREW J SAYKIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $547,090
- **Award type:** 5
- **Project period:** — → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9977803

## Citation

> US National Institutes of Health, RePORTER application 9977803, Neuroimaging Core (5P30AG010133-30). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9977803. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*